Charles Schwab Investment Management Inc Crispr Therapeutics Ag Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 723,032 shares of CRSP stock, worth $30.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
723,032
Previous 724,241
0.17%
Holding current value
$30.3 Million
Previous $34 Million
16.38%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding CRSP
# of Institutions
488Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$376 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$367 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$160 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$117 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$115 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.27B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....